Neogenomics (NEO) Free Cash Flow Growth (1y) (2011 - 2026)
Neogenomics (NEO) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 234.15 Bn | 230.09 Bn | 8.34 Bn | 51.58% |
| 2 | Danaher | 152.10 Bn | 147.75 Bn | 3.61 Bn | 16.06% |
| 3 | Natera | 48.48 Bn | 47.38 Bn | 486.15 Mn | -173.96% |
| 4 | Agilent Technologies | 44.35 Bn | 42.55 Bn | 990.00 Mn | 87.85% |
| 5 | Iqvia Holdings | 43.68 Bn | 41.60 Bn | 1.44 Bn | 23.29% |
| 6 | Idexx Laboratories | 43.02 Bn | 42.83 Bn | 779.09 Mn | 112.68% |
| 7 | Illumina | 34.39 Bn | 33.22 Bn | 770.00 Mn | -21.08% |
| 8 | Mettler Toledo International | 28.29 Bn | 28.24 Bn | 650.22 Mn | 33.01% |
| 9 | Labcorp Holdings | 27.51 Bn | 27.37 Bn | 1.11 Bn | -42.16% |
| 10 | Neogenomics | 2.42 Bn | 2.28 Bn | 91.88 Mn | -16.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.18% |
| Mar 31, 2026 | 55.96% |
| Dec 31, 2025 | -262.87% |
| Sep 30, 2025 | 136.70% |
| Jun 30, 2025 | 1,620.76% |
| Mar 31, 2025 | 5.31% |
| Dec 31, 2024 | -116.77% |
| Sep 30, 2024 | 84.11% |
| Jun 30, 2024 | 109.00% |
| Mar 31, 2024 | -39.26% |
| Dec 31, 2023 | 230.51% |
| Sep 30, 2023 | 59.48% |
| Jun 30, 2023 | 66.87% |
| Mar 31, 2023 | 39.29% |
| Dec 31, 2022 | 74.12% |
| Sep 30, 2022 | -6.03% |
| Jun 30, 2022 | -20.02% |
| Mar 31, 2022 | -173.54% |
| Dec 31, 2021 | -475.42% |
| Sep 30, 2021 | -210.24% |